Charakterystyka i podział rekombinowanych preparatów krzepnięcia zarejestrowanych w Polsce w leczeniu hemofilii A i B z uwzględnieniem nowej klasy czynnika uzyskiwanego z komórek ludzkich

*Paweł Łaguna¹, Maciej Trzaska²

Summary
Developments in haemophilia treatment during last 30 years are an example of spectacular medical success. The introduction of new drugs in clinical practice and treatment of children, as well as regular prophylaxis, has made a significant improvement in patients quality of life. Progress has been observed not only in methods of treatment but also in factor concentrates. Lyophilised plazma-derived factors were followed by recombinant factors. New generations of these recombinant factors differed amongst themselves by amounts of plasma content. As a result, virological safety of rFVIII concentrates in replacement therapy in haemophilia. A patients has greatly improved and the risk of blood-borne pathogen transmission in these patients has virtually been abolished. Currently clinical studies are being performed on a new generation of recombinant products fully derived from human cells. This article reviews characteristics of different generations of recombinant factors VIII and IX registered in Poland.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.